Skip to main content

Advertisement

Figure 8 | Journal of Neuroinflammation

Figure 8

From: Hydrogen sulfide-releasing cyclooxygenase inhibitor ATB-346 enhances motor function and reduces cortical lesion volume following traumatic brain injury in mice

Figure 8

Effect of ATB-346 on brain edema, infarction and locomotor activity. Representative TTC stained brain section (four out of the six consecutive sections from cranial to caudate region) corresponding to largest infraction from each group (A). Brain sections (2 mm thick) were stained with TTC at 24 hours after TBI and show significant difference after ATB-346 treatment in terms of area (B) and volume (C) of infarctions. The figures are representative of at least three experiments performed on different experimental days. TBI determined a range of impairments in locomotor tasks, as showed by the EBST (D) and the rotarod test (E), after seven days. Both groups of animals that received naproxen or ATB-346 were significantly less impaired in EBST and rotarod tests compared with the TBI group. ATB-346-treated mice displayed significant improvement in their behavioral performance as revealed by decreased biased swing activity in the EBST (D) and increased time on the rotating rod in the rotarod test (E). Each data are expressed as mean ± SEM from N = four male CD mice for each group. A P value of less than 0.05 was considered significant. ***P <0.001 versus sham, ###P <0.001 versus TBI.

Back to article page